Principal and Founder, Hull Associates, LLC
Stephen Hull has over 25 years of experience in health policy and medical product strategy, for medical devices and diagnostics, as well as pharmaceuticals and biotech products. He is Principal and Founder of Hull Associates, a specialized global reimbursement strategy firm focused on medical device and diagnostic technologies. With 40 seasoned consultants worldwide, his firm routinely assists in the development and execution of comprehensive strategies for product launch and reimbursement in major global markets.
Prior to forming Hull Associates, he served as Sr. Vice President for Global Reimbursement at AdvaMed, in Washington, D.C., the leading U.S.-based medical technology trade association. In that capacity, he worked with every major medical device company in the industry for common reimbursement policy issues in all major therapeutic areas. Internationally, he designed and launched numerous joint advocacy campaigns, with a primary focus on reimbursement issues, working with sister associations in the major overseas markets.
Before his trade association work, Mr. Hull was a Principal at Covance Health Economics and Outcomes Services, where he executed numerous private and public payor reimbursement and market strategies for pharmaceutical, biotech and medical device products, from nephrology, cardiology and oncology, to treatments for obesity and ophthalmic indications. Mr. Hull has served in the past as a committee chair for the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) and is a frequent speaker at industry seminars on reimbursement issues internationally. He has an advanced degree in health policy from the Johns Hopkins Bloomberg School of Public Health, and a bachelor’s degree in international relations and French from Colgate University.
Healthcare is changing dramatically and the Medicare program is moving rapidly as well to adapt to new incentives for quality and improved efficiency. This session will address major trends in payment systems and their impact on medical devices and diagnostics and will explore the latest developments in the Physician Fee Schedule proposed rule, the Hospital […]